Clinical trials: SLE (Systemic Lupus)
Lupus Erythematosus, Systemic
Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus (SLE) who had participated in the main…
- Trial name
- IP-006 (NCT03427151)
- Testing
- IPP-201101
- Where
- 14 sites in United States, Czechia and 5 more
- Volunteers
- 62 people
- Sponsor
- ImmuPharma
Systemic Lupus Erythematosus, Systemic Scleroderma
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Our study aims at defining the role of circulating microparticles in the physiopathology of two rare auto-immune diseases: systemic lupus erythematosus (SLE) and systemic scleroderma (SSc).
- Trial name
- MICROLUPS (NCT03575156)
- Testing
- blood sample, urine sample
- Where
- France
- Volunteers
- 208 people
- Sponsor
- University Hospital, Bordeaux
Systemic Lupus Erythematosus, Lupus Nephritis
Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune system dysregulation and inflammation affecting multiple organs.
- Trial name
- NCT07805863
- Volunteers
- 90 people
- Sponsor
- Assiut University
Lupus Erythematosus, Systemic
Chinese Rheumatism Biobank(CRB)
Early prediction of major organ damage in SLE needs to dynamically track the evolution of SLE patients before and after the onset of major organ damage, and analyze the microscopic molecular evolution patterns synchronized with…
- Trial name
- NCT06887517
- Testing
- Antimalarial with or without oral glucocorticosteroid
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erythematosus
CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have autoantibody positive, clinically-active…
- Trial name
- NCT02074020
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
Systemic, Lupus
Aerobic Exercise Versus Whole-Body Vibration on Fatigue, Functional Capacity, Quality of Life in Systemic Lupus
PURPOSE: … The aim of this study will be conducted to investigate the therapeutic efficacy of Aerobic exercise versus whole-body vibration on fatigue, functional capacity and quality of life in patients with systemic lupus…
- Trial name
- NCT05321108
- Testing
- Group A (GA)(Aerobic exercise group), Group B (GB) (Whole-body vibration (WBV) group)
- Where
- Egypt
- Volunteers
- 68 people
- Sponsor
- Cairo University
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome
This is a Phase I-II open- label single-dose study in subjects with significant refractory Rheumatoid Arthritis (RA), relapsing Systemic Lupus Erythematosus (SLE) or Sharp's Syndrome (SS).
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
- Trial name
- NCT02741362
- Testing
- Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Arkansas Heart Hospital
SLE
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
This is a case-control study investigating serum IL-33 levels and their association with clinical manifestations in systemic lupus erythematosus (SLE).
- Trial name
- NCT07149402
- Volunteers
- 150 people
- Sponsor
- Assiut University
Lupus
Cardiac Imaging in Systemic Disorders: the ORACLES Registry
Autoimmune diseases affect a total of 5 to 10% of the population. These diseases are associated with an increased risk of developing cardiovascular pathologies.
- Trial name
- ORACLES (NCT07134166)
- Testing
- data collection
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus
Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
The purpose of this study is to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus and refractory thrombocytopenia
- Trial name
- NCT05929248
- Testing
- Telitacicept, conventional therapy
- Volunteers
- 64 people
- Sponsor
- Guanmin Gao
Glomerulonephritis, Membranoproliferative, Lupus Nephritis
BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
The purpose of this study is to investigate whether the experimental drug BG9588 can be used to treat lupus nephritis more effectively and with less toxicity than standard treatments, including cyclophosphamide (Cytoxan)…
- Trial name
- NCT00001789
- Testing
- BG9588
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Refractory Systemic Lupus Erythematosus
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
This is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT06530849
- Testing
- GC012F Injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Lupus Erythematosus, Systemic
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
The purpose of this study is: 1. To assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood. 2.
- Trial name
- NCT00065806
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Laura Schanberg
Systemic Lupus Erythematosus, Lupus
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
The purpose of this study is to find the best way to prevent heart disease and stroke in people with lupus (systemic lupus erythematosis, or SLE).
- Trial name
- NCT00054938
- Testing
- pravastatin, aspirin, ramipril
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Brigham and Women's Hospital
Lupus Nephritis
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
An open-label study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Lupus Nephritis
- Trial name
- NCT01226147
- Testing
- Tamibarotene
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kinki University
Lupus Nephritis
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
Introduction and background : Glomerulonephritis and auto-immune diseases are often associated. Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which have a severe impact on…
- Trial name
- GOODLUPUS (NCT03664908)
- Testing
- Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Systemic Lupus Erythematosus
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus
Cognitive impairment occurs in as many as 80% of lupus patients and affective disorders, depression and anxiety, are also common. Both of these problems contribute significantly to disease burden and disability.
- Trial name
- NCT02456168
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Systemic Lupus Erythematosus (SLE)
Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a highly variable presentation and course. It can affect virtually every organ of the body and many symptoms may be observed.
- Trial name
- NCT05724940
- Testing
- clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients
- Volunteers
- 150 people
- Sponsor
- Sohag University
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease…
- Trial name
- PHOENYCS FLY (NCT06617325)
- Testing
- DZP
- Where
- 242 sites in United States, Argentina and 21 more
- Volunteers
- 450 people
- Sponsor
- UCB Biopharma SRL
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
- Trial name
- SKINDLE (NCT01597050)
- Testing
- R932333
- Where
- 15 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Rigel Pharmaceuticals